Dr. Mehmet Sitki Copur on the Most Exciting Research Presented at ASCO 2019

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Cancer Network spoke with Mehmet Sitki Copur, MD, FACP, medical oncologist at the Morrison Cancer Center, about the most exciting research presented at ASCO in 2019.

Cancer Network spoke with Mehmet Sitki Copur, MD, FACP, medical oncologist/hematologist at Mary Lanning Healthcare Center's Morrison Cancer Center, adjunct professor at the University of Nebraska Medical Center, and Editor-at-Large as well as a member of ONCOLOGY's Community Oncology Board, about the most exciting research presented at ASCO 2019.

Recent Videos
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content
Telehealth Groups May Improve the Social Lives of Young Cancer Populations

Telehealth Groups May Improve the Social Lives of Young Cancer Populations

Tim Cortese
April 3rd 2025
Article

Most patients with cancer who took part in a telehealth group expressed that they liked the members of their group and felt less social isolation.

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

Ariana Pelosci
April 1st 2025
Article

An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.

PIPAC-MMC Plus FOLFIRI Shows Feasibility, Safety in Peritoneal Metastases

Roman Fabbricatore
March 31st 2025
Article

Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

Tim Cortese
March 31st 2025
Article

A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.